Quince Therapeutics

Quince Therapeutics

Quarterly Financials

Values in thousands2026-03-312025-12-312025-09-302025-06-30
Revenue
$0
$0
$0
$0
Gross Profit
-36
-36
-35
EBITDA
30,609
-11,328
-15,947
EBIT
30,573
-11,364
-15,982
Net Income
35,912
-39,458
-13,442
-16,049
Net Change In Cash
0
0
0
0
Free Cash Flow
-7,627
-10,485
-10,002
-11,541
Cash
18,163
5,809
6,452
16,826
Basic Shares
250
278
269
233

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$0
$0
$0
$0
Gross Profit
-142
-186
-322
-175
EBITDA
-80,623
-35,984
-26,820
-50,986
EBIT
-80,765
-36,170
-27,142
-51,190
Net Income
-83,979
-56,828
-31,385
-51,660
Net Change In Cash
0
0
0
0
Cost of Revenue
-25,329
Free Cash Flow
-41,777
-32,161
-18,452
-44,171
Cash
5,809
6,212
20,752
44,579
Basic Shares
250
216
186
167

Earnings Calls

QuarterEPS
2026-03-31
$57.60
2025-12-31
-$0.40
2025-09-30
-$0.25
2025-06-30
-$0.34